Diana L. Hanna
YOU?
Author Swipe
View article: 573 Phase 1 study of GEN2, a personalizing systemic cancer immunotherapy, in adult patients with advanced solid tumor malignancies
573 Phase 1 study of GEN2, a personalizing systemic cancer immunotherapy, in adult patients with advanced solid tumor malignancies Open
View article: Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study Open
Intensity Therapeutics, Inc.
View article: Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer Open
Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerg…
View article: A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer
A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer Open
SUMMARY Background In this Phase II randomized clinical trial, we evaluated a medically supervised ketogenic diet (MSKD) compared to a usual diet (non-MSKD) when combined with the triplet chemotherapy regimen of gemcitabine, nab-paclitaxel…
View article: Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer Open
View article: Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial Open
There is a need for novel therapies for patients with previously treated HER2-positive gastroesophageal adenocarcinoma (GEA). This phase 1 (NCT02892123) dose-escalation and expansion trial evaluated zanidatamab (a dual HER2-targeted bispec…
View article: Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response Open
PURPOSE After neoadjuvant therapy (NAT) and surgery, up to one third and one half of patients with esophagogastric adenocarcinoma with a pathologic complete response (pCR; tumor regression grade 0 [TRG-0]) and near-pCR (TRG-1) will recur, …
View article: 1497 Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
1497 Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors Open
View article: Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma Open
Introduction Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In this retrosp…
View article: 782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors Open
Background Systemic activation of multiple immune receptors, such as Toll-like (TLR), Nucleotide oligomerization domain (NOD)-like, and Stimulator of interferon genes (STING) may be required for efficient anti-tumor immune responses. Decoy…
View article: 611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1
611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1 Open
Background Aldesleukin requires high systemic doses (8.4 million IU/kg equaling 0.518 mg/kg per weekly cycle) to achieve therapeutic benefit; however, such doses typically result in life-threatening toxicities. 'Non-α' interleukin-2 (IL-2)…
View article: Supplementary Figure S1 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S1 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for VEGFB mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
View article: Supplementary Figure S8 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S8 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for VEGFB mRNA levels in CLM for OS (complete response, CR; standard error, SE)
View article: Supplementary Table 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Supplementary Table 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Open
PDF - 86KB, LCP1 polymorphisms and outcome in patients with stage II or III colon cancer (USC cohort).
View article: Supplementary Table 1 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Supplementary Table 1 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Open
PDF - 85KB, Primer sequences and region of Plastin polymorphisms.
View article: Supplementary Figure S4 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S4 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for KDR mRNA levels in CLM for RFS (complete response, CR)
View article: Supplementary Figure S6 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S6 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for EPHB4 mRNA levels in CLM for RFS (complete response, CR)
View article: Supplementary Figure S7 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S7 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for ACVRL1 mRNA levels in CLM for OS (complete response, CR; standard error, SE)
View article: Supplementary Table 1, Supplementary Table 2A, Supplementary Table 2B, Supplementary Table 3, Supplementary Table 4, or Supplementary Table 5 from <i>TWIST1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
Supplementary Table 1, Supplementary Table 2A, Supplementary Table 2B, Supplementary Table 3, Supplementary Table 4, or Supplementary Table 5 from <i>TWIST1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy Open
Supplementary Table 1. Summary of EMT-related SNPs Supplementary Table 2A. Association between baseline characteristics and clinical outcomes in the bevacizumab cohort Supplementary Table 2B. Association between baseline characteristics an…
View article: Data from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
Data from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Open
Circulating tumor cells (CTC) express epithelial and stem cell–like genes, though current approved detection methods mainly use epithelial markers. We optimized a CTC isolation method that could capture their molecular heterogeneity and pr…
View article: Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Open
PDF - 56KB, Time-to-tumor recurrence (TTR) by LCP111342 in USC cohort (Training set) stage II/III CRC male patients treated with 5-fluorouracil (5-FU)-based chemotherapy.
View article: Supplementary Figure S3 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S3 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for HIF1A mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
View article: Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Open
ROC curve stratified by combination of CK20 and Survivin gene expression: An optimal cutoff value of either 0.16 for CK20 or 0.15 for Survivin yields a sensitivity of 79.6% and specificity of 85%.
View article: Supplementary Figure S5 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S5 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for EGFL7 mRNA levels in CLM for RFS (complete response, CR)
View article: Supplementary Figure S2 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S2 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for VEGFC mRNA levels in CLM for RFS (complete response, CR; not reached, NR)
View article: Data from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Data from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Open
Tumor recurrence after curative resection remains a major problem in patients with locally advanced colorectal cancer treated with adjuvant chemotherapy. Genetic single-nucleotide polymorphisms (SNP) may serve as useful molecular markers t…
View article: Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
Supplementary Figure 1 from Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Open
ROC curve stratified by combination of CK20 and Survivin gene expression: An optimal cutoff value of either 0.16 for CK20 or 0.15 for Survivin yields a sensitivity of 79.6% and specificity of 85%.
View article: Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Supplementary Figure 2 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy Open
PDF - 56KB, Time-to-tumor recurrence (TTR) by LCP111342 in USC cohort (Training set) stage II/III CRC male patients treated with 5-fluorouracil (5-FU)-based chemotherapy.
View article: Data from <i>TWIST1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy
Data from <i>TWIST1</i> Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy Open
The epithelial–mesenchymal transition (EMT) is an important mechanism of resistance to angiogenesis inhibition. The ability of EMT pathway genetic variants to predict the efficacy of antiangiogenic therapy is unknown. We analyzed associati…
View article: Supplementary Figure S1 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Supplementary Figure S1 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection Open
Kaplan Meier curves for VEGFB mRNA levels in CLM for RFS (complete response, CR; not reached, NR)